Second-line Chemotherapy for Advanced Bladder Cancer: Taxanes Versus Vinflunine

Basit Öğe Kaydı
dc.contributor.authorDemir, Bilgin
dc.contributor.authorAytaç, Ali
dc.contributor.authorÇolak, Gökhan
dc.contributor.authorBalçık, Onur Yazdan
dc.contributor.authorAcar, Omer
dc.date.accessioned2026-01-24T12:00:49Z
dc.date.available2026-01-24T12:00:49Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractAim: Second-line chemotherapy in advanced urothelial carcinoma (UC) remains a significant clinical challenge, with limited high-level evidence guiding regimen selection. Vinflunine is the only agent approved by the European Medicines Agency for this setting, while taxanes are widely used off-label based on phase 2 data. Methods: We conducted a retrospective analysis of patients with metastatic bladder cancer treated at Aydın Adnan Menderes University between 2013 and 2022. Eligible patients had received at least three months of second-line chemotherapy with either vinflunine or taxane-based regimens (docetaxel or paclitaxel). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events were compared between groups. Results: Among 38 patients receiving second-line therapy, 25 (65.8%) were treated with taxanes and 13 (34.2%) with vinflunine. Median PFS was significantly longer in the taxane group (4.9 vs. 2.2 months; p=0.001). Median OS favored taxanes numerically (13.2 vs. 4.33 months) but did not reach statistical significance (p=0.068). ORR was higher in the taxane group (52% vs. 23.1%), but the difference was not statistically significant (p=0.87). Adverse event profiles were consistent with known toxicities. Conclusion: This single-center retrospective study suggests that taxane-based regimens may offer superior PFS compared to vinflunine in the second-line treatment of advanced UC, despite the lack of statistically significant OS benefit. Given limitations in access to immunotherapy and targeted agents, cytotoxic chemotherapy remains essential, underscoring the need for further prospective trials to define optimal second-line strategies.
dc.identifier.doi10.4274/ahot.galenos.2025.2025-7-2
dc.identifier.endpage155
dc.identifier.issn3061-9947
dc.identifier.issue2
dc.identifier.startpage150
dc.identifier.trdizinid1333630
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1333630
dc.identifier.urihttps://doi.org/10.4274/ahot.galenos.2025.2025-7-2
dc.identifier.urihttps://hdl.handle.net/20.500.12868/3728
dc.identifier.volume58
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofActa haematologica oncologica Turcica
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_TR-Dizin_20260121
dc.subjectUrothelial carcinoma
dc.subjecttaxanes
dc.subjectsecond-line chemotherapy
dc.subjectvinflunine
dc.titleSecond-line Chemotherapy for Advanced Bladder Cancer: Taxanes Versus Vinflunine
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu